New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
14:25 EDTCTRP, SWKS, RPRX, PII, LXKOptions with decreasing volatility: CTRP SWKS RPRX PII LXK
News For CTRP;SWKS;RPRX;PII;LXK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
10:08 EDTCTRPCtrip.com threatened by Alibaba partnership with Shiji, Forbes says
Subscribe for More Information
07:55 EDTSWKSAvago RF Micro Skyworks should be bought ahead of results, says Pacific Crest
Subscribe for More Information
October 23, 2014
14:00 EDTRPRXRepros Therapeutics volatility elevated as shares trade near two-year low
Repros Therapeutics overall option implied volatility of 158 is above its 26-week average of 93 according to Track Data, suggesting large price movement.
October 22, 2014
06:17 EDTPIIPolaris Industries reports Q3 Off-Road Vehicle sales up 17% to $823.2M
Subscribe for More Information
06:11 EDTPIIPolaris Industries raises FY14 EPS to $6.55-$6.65 from $6.48-$6.58
FY14 EPS consensus of $6.58; Narrows low end of FY14 sales guidance to 17%-18% growth from 16%-18%, consensus $4.43B.
06:09 EDTPIIPolaris Industries reports Q3 EPS cont ops $2.06, consensus $2.02
Subscribe for More Information
October 21, 2014
18:36 EDTRPRXOn The Fly: After Hours Movers
Subscribe for More Information
16:11 EDTRPRXRepros Therapeutics: Results from Androxal study exhibit positive safety profile
Repros Therapeutics reported results from a large, controlled, long-term safety study comparing Androxal to a placebo. In this study of Androxal, ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. The last patient completed this study in late September. The Company's planned NDA will include study ZA-303, which will provide a significant portion of the support of long-term safety by providing data from 141 subjects exposed for one year or more. Over 200 subjects reached this milestone in the entire exposure database. ICH guidance for drugs to treat non-life-threatening conditions suggests that a minimum of 100 subjects should be exposed to the drug for one year.
14:04 EDTSWKSEarnings Preview: Analysts divided on Broadcom ahead of Q3 report
Subscribe for More Information
10:00 EDTCTRPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:08 EDTCTRPCtrip.com initiated with a Buy at Citigroup
Subscribe for More Information
06:36 EDTLXKLexmark raises FY14 adjusted EPS view to $4.05-$4.15 from $3.95-$4.15
Subscribe for More Information
06:34 EDTLXKLexmark sees Q4 adjusted EPS $1.10-$1.20, consensus $1.18
Sees Q4 revenue down 2%-4%. The company expects the 2012 decision to exit inkjet to have a diminishing negative impact on revenue growth. Excluding Inkjet Exit revenue, Q4 revenue is expected to grow year to year.
06:33 EDTLXKLexmark reports Q3 adjusted EPS $1.05, consensus 92c
Reports Q3 revenue $918.1M, consensus $889.62M. Paul Rooke, Lexmark chairman and CEO, said, "In Q3, Managed Print Services and Perceptive Software combined revenue grew 20%, representing nearly one third of Lexmark's total revenue, and is on track to exceed $1B this year. The acquisition of ReadSoft further broadens Lexmark's solutions capabilities and reach, and supports our target of generating Perceptive Software revenue of $500M in 2016"
October 20, 2014
18:51 EDTSWKSOn The Fly: After Hours Movers
Subscribe for More Information
18:22 EDTSWKSSkyworks Solutions, Cirrus Logic, others higher after Apple reports Q4 results
The following stocks are moving higher in the after hours following Apple's Q4 results: ARM Holdings (ARMH) is up 1.1%, Skyworks Solutions (SWKS) is higher by 2.2% ,NXP Semiconductors (NXPI), up 2.28%,Cirrus Logic (CRUS) is up 2%, RF Micro Devices (RFMD) gains 1.53% and Avago Technologies (AVGO) is up 1.17%.
16:24 EDTCTRPPriceline raises stake in Ctrip.com to 7.9% from 6.88%
October 17, 2014
09:17 EDTRPRXOn The Fly: Pre-market Movers
Subscribe for More Information
October 16, 2014
20:03 EDTRPRXRepros Therapeutics upcoming meeting with FDA to be Type C, not Type B
Subscribe for More Information
07:41 EDTRPRXRepros Therapeutics management to meet with Brean Capital
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use